Pembrolizumab Does Not Improve Upon Lenvatinib in Advanced HCC
Adding pembrolizumab to first-line treatment with lenvatinib did not improve outcomes in a phase 3 trial of patients with advanced HCC.
Adding pembrolizumab to first-line treatment with lenvatinib did not improve outcomes in a phase 3 trial of patients with advanced HCC.
Patients who received the vaccine plus Keytruda were 49 percent less likely to die or have their cancer return after three years.
Adding toripalimab to first-line chemotherapy improved survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Adding atezolizumab to treatment with carboplatin improved survival outcomes in patients with metastatic TNBC in a phase 2 trial.
Lymphedematous extremity 2.65 times as likely as the nonlymphedematous extremity to have skin cancer.
Researchers determined use of a home pain monitoring app led to less clinically significant pain in children with cancer.
Researchers sought to determine the prevalence of reduced function among survivors of ALL and NHL by treatment decade.
Survival similar among racial and ethnic groups; ECOG performance status linked to survival.
An assessment of nurse practitioners’ preferences for in-person or telehealth care delivery showed mixed satisfaction, but most of those who provided both preferred in-person.
Radiation-induced lung injury (RILI) is a complication of radiation therapy and can develop as radiation pneumonitis or pulmonary fibrosis.